Comparative Pharmacology
Head-to-head clinical analysis: PERCODAN versus TARGINIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERCODAN versus TARGINIQ.
PERCODAN vs TARGINIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone acts on the central nervous system (CNS) to produce analgesia. Aspirin inhibits cyclooxygenase, leading to decreased prostaglandin synthesis, which reduces pain and inflammation.
TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.
1-2 tablets orally every 4-6 hours as needed for pain. Each tablet contains oxycodone 4.5 mg and aspirin 325 mg.
1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.
None Documented
None Documented
Oxycodone: 3-5 hours, prolonged in elderly, hepatic/renal impairment. Aspirin: 2-3 hours at low doses; 15-30 hours at anti-inflammatory doses due to saturable metabolism.
Oxycodone terminal half-life is 3.5-4.0 hours; naloxone half-life is 1-1.5 hours. The prolonged-release formulation yields a longer apparent half-life, supporting twice-daily dosing.
Oxycodone: primarily renal (65-87% as parent and metabolites, mostly noroxycodone and oxymorphone conjugates); ~10% fecal. Aspirin: renal (75-90% as salicylates and metabolites, dose-dependent).
Oxycodone is primarily excreted renally as noroxycodone and free oxycodone; naloxone undergoes extensive hepatic metabolism and is excreted renally as naloxone-3-glucuronide. For TARGINIQ, approximately 87% of the dose is eliminated in urine: 19% as unchanged oxycodone, 1% as unchanged naloxone, and the remainder as metabolites. Fecal excretion accounts for ~10%.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination